These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30512190)

  • 1. On high-risk, low-grade glioma: What distinguishes high from low?
    Geurts M; van den Bent MJ
    Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-grade glioma.
    Kumthekar P; Raizer J; Singh S
    Cancer Treat Res; 2015; 163():75-87. PubMed ID: 25468226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
    Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IDH in Low-Grade Glioma.
    Claus EB; Verhaak RGW
    N Engl J Med; 2023 Aug; 389(7):655-659. PubMed ID: 37585633
    [No Abstract]   [Full Text] [Related]  

  • 7. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grade II gliomas-not so low grade.
    Shonka NA
    Oncology (Williston Park); 2014 Dec; 28(12):1016. PubMed ID: 25510801
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular categorisation of gliomas.
    Burki TK
    Lancet Oncol; 2015 Jul; 16(7):e320. PubMed ID: 26095778
    [No Abstract]   [Full Text] [Related]  

  • 10. From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.
    Ferroli P; Acerbi F; Finocchiaro G
    World Neurosurg; 2010 Apr; 73(4):234-6. PubMed ID: 20849763
    [No Abstract]   [Full Text] [Related]  

  • 11. Does early identification of low-grade glioma growth impact outcome?
    Chamberlain MC
    Neuro Oncol; 2014 Sep; 16(9):1296. PubMed ID: 25125165
    [No Abstract]   [Full Text] [Related]  

  • 12. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?
    Labussiere M; Sanson M; Idbaih A; Delattre JY
    Oncologist; 2010; 15(2):196-9. PubMed ID: 20133500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.
    Kurimoto M; Suzuki H; Aoki K; Ohka F; Kondo G; Motomura K; Iijima K; Yamamichi A; Ranjit M; Wakabayashi T; Kimura S; Natsume A
    Cancer Invest; 2016; 34(1):12-5. PubMed ID: 26695622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.